Business Context and Reporting Period
cbdMD, Inc. (YCBD), an emerging growth company incorporated in North Carolina, filed this Form 8-K on June 28, 2021. The report details the entry into a material definitive agreement for a firm commitment underwritten public offering of preferred stock.
Key Financial Metrics and Transaction Details
- Security Issued: 1,913,100 shares of 8.0% Series A Cumulative Convertible Preferred Stock (plus 286,900 shares via over-allotment option).
- Offering Price: $7.50 per share.
- Expected Net Proceeds: Approximately $15.1 million (including over-allotment), after deducting underwriting discounts, commissions, and estimated expenses.
- Underwriting Fees: 7.25% of gross cash proceeds.
- Representative Warrant: Issued to purchase 143,482 shares of common stock at an exercise price of $3.75 per share.
- Estimated Expenses: Approximately $215,000 (excluding underwriting discounts) plus up to $105,000 in reimbursable out-of-pocket fees.
- Use of Proceeds: General working capital.
- Closing Date: Expected July 1, 2021.
Material Changes and Agreements
The primary material change is the execution of an Underwriting Agreement with ThinkEquity, a division of Fordham Financial Management, Inc. The over-allotment option was exercised on June 29, 2021. Additionally, the Company and certain executive officers entered into Lock-Up Agreements restricting the sale of securities for 60 days from the closing date.
Outlook, Risks, and Contingencies
The filing contains forward-looking statements regarding the expected net proceeds, which are subject to risks and uncertainties detailed in the Company's other SEC filings. The transaction is contingent upon the satisfaction of customary closing conditions. The Company intends to utilize the capital raised for general working capital purposes.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received on or after July 1, 2021.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific representations, warranties, and termination provisions.
- Confirm the terms of the 8.0% Series A Cumulative Convertible Preferred Stock, including conversion mechanics and dividend rights.
- Monitor the impact of the new preferred stock issuance on the Company's capital structure and potential dilution to common shareholders.
- Check subsequent filings for the utilization of proceeds and any changes to the Company's liquidity position.